Cookies on this site

HIT (Hepatitis C Inoculum Trial)

 

No. of participants:

Up to 10

Location:

Oxford

Duration:

Six months per participant. Enrolling 2026-27

What is the purpose of this study and why participate?

AdobeStock_1902867189.jpeg There is currently no vaccine for hepatitis C virus (HCV), and it is not feasible to conduct large clinical trials of new vaccines in naturally infected people. A Controlled Human Infection Model (CHIM) where healthy volunteers are intentionally exposed to HCV would allow more efficient testing of new preventative vaccines or drugs.


Trial Information

REC reference: 25/SC/0383

Chief Investigator: Eleanor Barnes



Aims and outcomes

AdobeStock_1921470856.jpeg The purpose of this study is to collect blood from individuals with acute (short-term) and chronic (long-term) HCV infection. The plasma, which contains HCV, will be separated from the blood, tested, and stored for later use to establish HCV infection in future ethically-approved carefully monitored CHIM studies.

Location

The University of Oxford Experimental Medicine Clinical Research Facility (EMCRF)

Trial Partners

Centre for Immuuno-=Oncology logo